Stock AVANIR PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Avanir Pharmaceuticals Inc Stock

Equities

US05348P4019

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Avanir Pharmaceuticals Inc
2014 Otsuka : Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff RE
2014 NASDAQ OMX : names 14 stocks to test lower fee and rebate programme RE

Latest news about Avanir Pharmaceuticals Inc

Otsuka : Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff RE
NASDAQ OMX : names 14 stocks to test lower fee and rebate programme RE
Apple : Nasdaq slumps to worst day since July; S&P 500 dips RE
More news

Press releases Avanir Pharmaceuticals Inc

Avanir Pharmaceuticals : Announces Appointment of Rohan Palekar as President and Chief Executive Officer PR
Avanir Pharmaceuticals : Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer’s Disease PU
Avanir Pharmaceuticals : Announces JAMA Publication of Phase II Study Results Showing AVP-923 Significantly Reduced Agitation in Patients with Alzheimer's Disease PU
Avanir Pharmaceuticals : Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026 PU
Avanir Pharmaceuticals : Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II Study at Alzheimer's Association International Conference PU
More press releases

News in other languages on Avanir Pharmaceuticals Inc

Apple : Wall Street ouvre en légère hausse
Les valeurs à suivre mardi 2 décembre 2014 à Wall Street
AVANIR PHARMACEUTICALS : cédé au japonais Otsuka Pharmaceutical pour 3,5 milliards de dollars
Les valeurs à suivre sur les marchés américains
More news

Managers and Directors - Avanir Pharmaceuticals Inc

Managers TitleAgeSince
Dan Dalton CMP
 Compliance Officer - 16-05-31
Kelly Parker IRO
 Public Communications Contact - 15-05-31
Aneta Ferguson LAW
 General Counsel - 14-12-31
Members of the board TitleAgeSince
Donald Hayden CHM
 Chairman 68 -
Robert McQuade BRD
 Director/Board Member 67 -
Thomas DesRosier BRD
 Director/Board Member 69 -
More insiders

Company Profile

More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.54% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.01% 97.22B
ARGENX SE Stock argenx SE
+3.76% 22.27B
BIONTECH SE Stock BioNTech SE
-18.06% 20.84B
GENMAB A/S Stock Genmab A/S
-4.32% 19.19B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.05% 16.76B
BEIGENE, LTD. Stock BeiGene, Ltd.
-21.66% 14.76B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.20% 13.54B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.42% 11.53B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. Stock